Musculoskeletal disorders currently afflict approximately 1.71 billion individuals globally, representing a major public health and economic challenge, ...
Epirium Bio Inc. has obtained IND clearance from the FDA for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor.